Methyl 2-[3-[[1-(benzenesulfonamido)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]benzoate | 85850-25-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 2-[3-[[1-(benzenesulfonamido)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]benzoate
• CAS: 85850-25-5
• 化学式: C₂₁H₂₈N₂O₆S
• 分子量: 436.529
• InChiKey: UVHFNHDRKVVDPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  30
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  水杨酸甲酯 在 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 28.0h， 生成 Methyl 2-[3-[[1-(benzenesulfonamido)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]benzoate
  参考文献：
  名称：

  Ultra-short-acting .beta.-adrenergic receptor blocking agents. 3. Ethylenediamine derivatives of (aryloxy)propanolamines having esters on the aryl function

  摘要：

  Various ethylenediamine derivatives have been incorporated into the nitrogen substituent of certain short-acting (aryloxy)propanolamine systems that contain esters on their aryl functions. Although several of these compounds showed durations of action comparable to their prototypes, most of the nitrogen substituents significantly prolonged the duration of beta-adrenergic blockade. Similarly, while one of the compounds showed appreciable cardioselectivity in vitro, generally, little enhancement of cardioselectivity was obtained. A brief discussion of structure-activity relationships observed for the ethylenediamine derivatives is presented.

  DOI：

  10.1021/jm00362a004

文献信息

• ESTERS OF ARYLOXYPROPANOLAMINE DERIVATIVES AND USE AS BETA-ADRENERGIC BLOCKING AGENTS
  申请人：AMERICAN HOSPITAL SUPPLY CORPORATION

  公开号：EP0093155B1

  公开（公告）日：1986-08-27
• EP0093155A4
  申请人：——

  公开号：EP0093155A4

  公开（公告）日：1984-04-24
• US4906661A
  申请人：——

  公开号：US4906661A

  公开（公告）日：1990-03-06
• [EN] ESTERS OF ARYLOXYPROPANOLAMINE DERIVATIVES AND USE AS beta -ADRENERGIC BLOCKING AGENTS
  申请人：AMERICAN HOSPITAL SUPPLY CORPORATION

  公开号：WO1983001772A1

  公开（公告）日：1983-05-26

  (EN) Compounds of the formula$(10,)$wherein R1 is lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower alkyl carboxymethyl, aryl carboxymethyl, aryl, or aralkyl; A is a direct bond, lower alkylene, or lower alkenylene; x is 1 or 2, provided that when x is greater than 1, different occurences of the R1-O-C-A- group may be the same or different; Ar is heterocyclic, unsubstituted aromatic or aromatic substituted with lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halogen, acetamido, amino, nitro, lower alkylamino, hydroxy, lower hydroxyalkyl or cyano; W is alkylene containing from 1 to about 10 carbon atoms; and B is -NR2COR3, -NR2CONR3R4, -NR2SO2R3, -NR2SO2NR3R4, or -NR2COOR5, wherein R2, R3, R4 and R5 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, alkoxyaryl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R3 and R5 are not hydrogen when B is -NR2SO2R3 or -NR2COOR5, or R3 and R4 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof. The compounds of the present invention are beta-adrenergic blocking agents useful in the treatment of cardiac disorders, glaucoma, or the lowering of elevated intraocular pressure. (FR) Composé de formule$(10,)$où R1 est un alkyle inférieur, un cycloalkyle inférieur, un alkényle inférieur, un alkynyle inférieur, un alkyle carboxyméthyl inférieur, un aryle carboxyméthyl, un aryle ou un aralkyle; A est une liaison directe, un alkylène inférieur ou un alkénylène inférieur; x est égal à 1 ou 2, étant entendu que lorsque x est supérieur à 1, différentes représentations du groupe R1-O-C-A- peuvent être identiques ou différentes; Ar est un groupe hétérocyclique, aromatique non substitué ou aromatique substitué avec un alkyle inférieur, alkényle inférieur, alkynyle inférieur, alcoxy inférieur, halogène, acétamido, amino, nitro, alkylamino inférieur, hydroxy, hydroxyalkyle inférieur ou cyano; W est un alkylène contenant de 1 à 10 atomes de carbone environ; et B représente -NR2COR3, -NR2CONR3R4, -NR2SO2R3, -NR2SO2NR3R4, ou -NR2COOR5, où R2, R3, R4 et R5 peuvent être identiques ou différents et peuvent représenter l'hydrogène, un alkyle, un alcoxyalkyle, un alcoxyaryle, un cycloalkyle, un alkényle, un alkynyle, un aryle, un hétéroaryle, ou un aralkyle, sauf que R3 et R5 ne représentent l'hydrogène lorsque B représente -NR2SO2R3 ou -NR2COOR5, ou R3 et R4 peuvent former ensemble avec N un groupe hétérocyclique de 5 à 7 membres; et leurs sels pharmaceutiquement acceptables. Les composés de la présente invention sont des agents de blocage adrénergique beta utiles dans le traitement de troubles cardiaques, de glaucomes, ou dans l'abaissement de pressions intraoculaires élevées.
• Ultra-short-acting .beta.-adrenergic receptor blocking agents. 3. Ethylenediamine derivatives of (aryloxy)propanolamines having esters on the aryl function
  作者：Paul W. Erhardt、Chi M. Woo、William L. Matier、Richard J. Gorczynski、William G. Anderson

  DOI：10.1021/jm00362a004

  日期：1983.8

  Various ethylenediamine derivatives have been incorporated into the nitrogen substituent of certain short-acting (aryloxy)propanolamine systems that contain esters on their aryl functions. Although several of these compounds showed durations of action comparable to their prototypes, most of the nitrogen substituents significantly prolonged the duration of beta-adrenergic blockade. Similarly, while one of the compounds showed appreciable cardioselectivity in vitro, generally, little enhancement of cardioselectivity was obtained. A brief discussion of structure-activity relationships observed for the ethylenediamine derivatives is presented.